Utilization Of Antibody Allows Rapid Clearance Of Nanoparticle Probes From Blood Without The Need Of Probe Modifications

Nanoparticles are attracting attention as drug carriers for realizing "theranostics". However, nanoparticles generally show long blood circulation behaviors, and the remaining nanoparticle probe in the blood is the cause of prolonged optimal time from probe injection to imaging. Recently, it has been reported that some nanoparticles activate the immune system, producing an anti-nanoparticle antibody, which can selectively detect the corresponding nanoparticle and transfer it to the liver by opsonization. Lactosome is a polymer micelle prepared from amphiphilic PNMG-block-PLLA polydepsipeptide and known to activate the immune system when administered to mice at a specific concentration. In this study, radioactive fluorine-labeled lactosome (F-18-lactosome) is used as a positron emission tomography probe for tumor imaging, and anti-lactosome antibody was additionally administrated after 2 h from the probe dosage.F-18-lactosome remaining in the blood was opsonized by the anti-lactosome antibody and transferred to the liver under the antibody dose-dependent manner. Because of the probe reduction from the blood, the tumor/blood signal intensity ratio could be improved up to 50% by anti-lactosome antibody administration. There needs further improvement, but the developed method is applicable for imaging utilizing nanoparticle probes, which activate the immune system.